Trial
NCT05589844
A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Roswell Park Cancer Institute
Collaborators
—
Condition
Cytomegaloviral Infection
Intervention
Allogeneic Hematopoietic Stem Cell Transplantation
Why stopped
Study never approved
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-27